CSIMarket Company Name, Ticker, Suppliers, else..
 
Tiziana Life Sciences Ltd  (TLSA)
 
Price: $1.0146 $0.04 4.598%
Day's High: $1.0199999809265137 Week Perf: 2.48 %
Day's Low: $ 0.95 30 Day Perf: 4.6 %
Volume (M): 187,395 52 Wk High: $ 2.35
Volume (M$): $ 0 52 Wk Avg: $1.45
Open: $0.97 52 Wk Low: $0.87



 Market Capitalization (Millions $) -
 Shares Outstanding (Millions) -
 Employees 16
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -18
 Cash Flow (TTM) (Millions $) 0
 Capital Exp. (TTM) (Millions $) 0

Business Description


Tiziana Life Sciences Ltd is a biotechnology company that focuses on the development and commercialization of innovative therapies for diseases with high unmet medical need. The company is headquartered in London, United Kingdom, with operations in the United States and Italy. Tiziana Life Sciences primarily focuses on developing treatments for cancer, autoimmune and inflammatory diseases, and COVID-19. The company's pipeline includes potential therapies based on monoclonal antibodies and small molecules to target specific disease mechanisms. Tiziana Life Sciences aims to provide patients with safe and effective treatments that can improve their quality of life.


   Company Address: Clarendon House Hamilton HM 11
   Company Phone Number: 20 7495 2379   Stock Exchange / Ticker: TLSA


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
AZN   -0.19%    
GSK   -1.83%    
JNJ        2.85% 
NVS        4.13% 
PFE        1.81% 
SNY   -1.45%    
• View Complete Report
   



Clinical Study

Pioneering Hope in ALS Treatment Tiziana Life Sciences Submits IND Application for Intranasal Foralumab

Published Sat, Jun 14 2025 8:02 PM UTC

The landscape of drug development for neurodegenerative diseases such as Amyotrophic Lateral Sclerosis (ALS) is fraught with challenges, yet it is also imbued with the potential for groundbreaking advancements. On March 4, 2025, Tiziana Life Sciences, Ltd., a biotechnology company focused on innovative immunomodulation therapies, took a decisive step forward by filing an Inv...
Shares

Tiziana Life Sciences Chairman Shows Confidence with Share Purchase Amid Breakthroughs in Alzheimers Treatment,

Published Mon, May 12 2025 11:01 AM UTC

The Growing Commitment: Tiziana Life Sciences’ Chairman Boosts Stake Amid Promising Developments in Alzheimer s TreatmentIn a significant move reflective of confidence and support for Tiziana Life Sciences Ltd. (Nasdaq: TLSA), the company announced on May 12, 2025, that its Executive Chairman and Founder, Mr. Gabriele Cerrone, has acquired an additional 15,000 common share...
Clinical Study

Tizianas Intranasal Foralumab A Ray of Hope in Alzheimers Treatment with Reduced Microglia Activation,

Published Fri, May 9 2025 6:38 PM UTC

Promising Developments in Alzheimer s Treatment: Tiziana Life Sciences Intranasal Foralumab Shows Significant Reduction in Microglia ActivationTiziana Life Sciences, a biotechnology company known for its innovative therapeutic approaches, has announced promising developments in the treatment of Alzheimer s disease. The company recently revealed that a moderate Alzheimer s ...
Stock Market Announcement

Tiziana Life Sciences Charts a Fearless Course in Biotech with Innovative Intranasal Therapy and Strategic Financial Resilience,

Published Thu, Jan 23 2025 1:54 PM UTC

Tiziana Life Sciences Signals Positive Forward Trajectory with Strategic Capital Decision in Immunotherapy DevelopmentOn January 23, 2025, Tiziana Life Sciences, Ltd. (Nasdaq: TLSA), a notable contender in the biotechnology sector, issued a press release highlighting its decision to abstain from capital-raising activities in the near future. This announcement has significant...
Partnership

Tiziana Life Sciences Pioneering a Nasal Revolution in Immunomodulation

Published Fri, Feb 21 2025 5:36 PM UTC

In a strategic move that underscores its commitment to innovation in the biopharmaceutical sector, Tiziana Life Sciences has announced a collaborative agreement with Renaissance Lakewood, LLC, a notable player in Contract Development and Manufacturing Organizations (CDMO) specializing in nasal drug delivery. This partnership, revealed on February 21, 2025, centers around the...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) -
Price to Sales (Expected) -
Price to Book -
PEG (TTM) -

Financial Strength Current
Quick Ratio 0.36
Working Capital Ratio 0.76
Leverage Ratio (MRQ) 225.75
Total Debt to Equity -
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) 0 $
Revenues (TTM) -
Cash Flow (TTM) -
Cash -
Book Value -
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) -
Net Income per Employee (TTM) -1,151,938
Receivable Turnover Ratio (TTM) -
Inventory Turnover Ratio (TTM) -
Asset Turnover Ratio (TTM) -

Profitability Ratios Current
Gross Margin (MRQ) -
Operating Margin (MRQ) -
Net Margin (MRQ) -
Net Cash Flow Margin (MRQ) -
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -






Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.